|Bid||144.85 x 1000|
|Ask||144.86 x 800|
|Day's Range||144.48 - 146.35|
|52 Week Range||134.09 - 175.91|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||49.64|
|Earnings Date||Jan 31, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||5.64 (3.67%)|
|Ex-Dividend Date||Oct 13, 2022|
|1y Target Est||158.66|
AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.
Would you like a stock portfolio that generates enough passive income to fuel your retirement dreams? Unlike most areas of the economy, healthcare services are a top priority in good economic times and bad. Here's why investors who buy them now could end up with a big passive income stream that continues growing for the rest of their lives.
AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.